Abstract P1062: Pre-Pandemic Thrombo-inflammatory Biomarkers and Risk of Severe Covid-19: the Collaborative Cohort of Cohorts for Covid-19 Research (C4R)

M Mary Cushman Y Yuni Choi (Columbia University Irving Medical, New York, Minnesota, United States) D David Jacobs (University of Minnesota, Minnetonka, Minnesota, United States) A Alex Reiner (Department of Epidemiology, University of Washington, Seattle, WA, USA.) R Ryan Demmer (Mayo Clinic, Rochester, Minnesota, United States) R Russell Tracy N Nels Olson (Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States) M Margaret Doyle (University of Vermont, Burlington, Vermont, United States) D Debora Kamin Mukaz (Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States) L Laura Raffield N Nancy Min (University of Mississippi, Jackson, MS, USA.) V Vasan Ramachandran (The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States) V Vanessa Xanthakis A Andrew Johnson J Jason Umans (MedStar Health Research Institute, Bethesda, Maryland, United States) B Barry Make (Johns Hopkins University, Baltimore, MD, USA.) E Elizabeth Regan (National Jewish Health, Denver, CO, USA.) R Russell Bowler B Bharat Thyagarajan N Namratha Kandula (Northwestern University, Chicago, Illinois, United States) E Elizabeth Oelsner (Columbia University, New York, New York, United States)

Abstract

Background: Thrombo-inflammation is a hallmark of acute Covid-19, with higher thrombo-inflammatory markers during infection associated with adverse outcomes. We hypothesized that higher pre-pandemic biomarkers, reflecting a higher thrombo-inflammatory setpoint, might identify people at greater risk of severe manifestations of Covid-19. Hypothesis: Pre-pandemic inflammation markers are associated with risk of hospitalized or fatal (hereafter, “severe”) Covid-19 in a multi-ethnic US sample. Methods: From 2020-2023, C4R harmonized pre-pandemic measures and ascertained Covid-19 across 14 longstanding cohort studies. In 12 cohorts, we assessed biomarker data and covariates from the study visit closest to the pandemic for 6 analytes shown in the Table. HRs of severe Covid-19 by pre-pandemic biomarkers were estimated using cause-specific Cox regression, treating non-severe Covid-19 as a competing risk, and adjusting for pre-pandemic sociodemographic and clinical characteristics. Results: Biomarkers were measured a mean of 20 years before the pandemic with different sample sizes for each (Table footnote). Mean age at the start of the pandemic was in the 60s or 70s depending on the biomarker. The most represented race or ethnic groups were White and Black. The largest sample was for C-reactive protein, and there were 1,001 severe Covid-19 cases among 38,784 participants. In the adjusted models, considered individually, higher CRP, leukocyte count, factor VIII and fibrinogen, but not other markers, were associated with greater risk of severe Covid-19 (Table).Associations were robust across subgroups and time since biomarker measurement (example for C-reactive protein in Figure). Conclusions: In this prospective multi-study analysis of a multi-ethnic population, higher basal levels of thrombo-inflammation markers were associated with greater risk of severe Covid-19. Since we considered non-severe Covid-19 as a competing risk, associations may reflect factors related to progression to more serious Covid-19 illness.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue Suppl_1
Published March 11, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (21)

M

Mary Cushman

Y

Yuni Choi

Columbia University Irving Medical, New York, Minnesota, United States

D

David Jacobs

University of Minnesota, Minnetonka, Minnesota, United States

A

Alex Reiner

Department of Epidemiology, University of Washington, Seattle, WA, USA.

R

Ryan Demmer

Mayo Clinic, Rochester, Minnesota, United States

R

Russell Tracy

N

Nels Olson

Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States

M

Margaret Doyle

University of Vermont, Burlington, Vermont, United States

D

Debora Kamin Mukaz

Larner College of Medicine at the University of Vermont, Burlington, Vermont, United States

L

Laura Raffield

N

Nancy Min

University of Mississippi, Jackson, MS, USA.

V

Vasan Ramachandran

The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States

V

Vanessa Xanthakis

A

Andrew Johnson

J

Jason Umans

MedStar Health Research Institute, Bethesda, Maryland, United States

B

Barry Make

Johns Hopkins University, Baltimore, MD, USA.

E

Elizabeth Regan

National Jewish Health, Denver, CO, USA.

R

Russell Bowler

B

Bharat Thyagarajan

N

Namratha Kandula

Northwestern University, Chicago, Illinois, United States

E

Elizabeth Oelsner

Columbia University, New York, New York, United States